Antisense oligonucleotides in therapy for neurodegenerative disorders

Advanced Drug Delivery Reviews
Melvin M EversWilleke M C van Roon-Mom

Abstract

Antisense oligonucleotides are synthetic single stranded strings of nucleic acids that bind to RNA and thereby alter or reduce expression of the target RNA. They can not only reduce expression of mutant proteins by breakdown of the targeted transcript, but also restore protein expression or modify proteins through interference with pre-mRNA splicing. There has been a recent revival of interest in the use of antisense oligonucleotides to treat several neurodegenerative disorders using different approaches to prevent disease onset or halt disease progression and the first clinical trials for spinal muscular atrophy and amyotrophic lateral sclerosis showing promising results. For these trials, intrathecal delivery is being used but direct infusion into the brain ventricles and several methods of passing the blood brain barrier after peripheral administration are also under investigation.

References

Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·M L Stephenson, P C Zamecnik
Sep 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalJ Y Tang
Mar 1, 1990·Journal of Biochemical and Biophysical Methods·J M CampbellE Wickstrom
Nov 1, 1994·The Journal of Clinical Investigation·R R Lobb, M E Hemler
Apr 1, 1995·Annals of Neurology·B Cannella, C S Raine
May 22, 1995·FEBS Letters·P WittungB G Malmström
Sep 15, 1994·Biochemical Pharmacology·V V DemidovP E Nielsen
Aug 16, 1994·Biochemistry·N GustkeE Mandelkow
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·L WhitesellL M Neckers
Jan 1, 1996·Bioorganic & Medicinal Chemistry·B Hyrup, P E Nielsen
Jan 1, 1996·Antisense & Nucleic Acid Drug Development·R M HudziakD D Weller
Jun 1, 1997·Antisense & Nucleic Acid Drug Development·J Summerton, D Weller
Jan 15, 1999·Human Molecular Genetics·N SandovalD Schindler
Dec 10, 1999·Proceedings of the National Academy of Sciences of the United States of America·M TeplovaM Egli
Apr 25, 2000·Brain Research. Developmental Brain Research·Y L MullerA J Yool
May 11, 2000·Proceedings of the National Academy of Sciences of the United States of America·C WahlestedtJ Wengel
Sep 2, 2000·Current Opinion in Neurology·A Al-Chalabi, P N Leigh
Mar 10, 2001·Nature·E S LanderUNKNOWN International Human Genome Sequencing Consortium
Nov 24, 2001·Brain Research Bulletin·K H Fischbeck
Apr 25, 2002·Nucleic Acids Research·Jens KurreckVolker A Erdmann
May 23, 2002·Journal of the American Chemical Society·Dorte Renneberg, Christian J Leumann
Jun 21, 2002·Antisense & Nucleic Acid Drug Development·Beth M McMahonElliott Richelson
Jun 28, 2002·Nucleic Acids Research·Dorte RennebergChristian J Leumann
Jun 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Victor M MillerHenry L Paulson
Oct 21, 2003·Nucleosides, Nucleotides & Nucleic Acids·Miriam FriedenTroels Koch

❮ Previous
Next ❯

Citations

Jan 31, 2016·Experimental Neurology·Monika M Golas, Bjoern Sander
Jan 29, 2016·Nature Reviews. Molecular Cell Biology·Yishai AviorNissim Benvenisty
Feb 26, 2016·Brain : a Journal of Neurology·Julie W RuttenSaskia A J Lesnik Oberstein
Jan 14, 2016·Wiener medizinische Wochenschrift·Wen-Hann Tan, Lynne M Bird
Mar 8, 2016·ACS Chemical Biology·Frederic GeinguenaudLaurence Motte
Apr 5, 2016·Journal of Cancer Research and Clinical Oncology·Abdul Shukkur EbrahimAyad Al-Katib
Jul 15, 2015·Human Gene Therapy·Karin E LundinC I Edvard Smith
Apr 17, 2016·Nucleic Acids Research·Rudolph L Juliano
May 25, 2016·Human Genetics·Thomas GeuensVincent Timmerman
Jun 12, 2016·Nucleic Acids Research·Mallory A Havens, Michelle L Hastings
Jun 22, 2016·Molecular Therapy. Nucleic Acids·Maria Eugenia Gallo CantafioMaria Teresa Di Martino
Apr 26, 2016·British Journal of Clinical Pharmacology·Kannan Sridharan, Nithya Jaideep Gogtay
Sep 19, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·João Casaca-CarreiraYasin Temel
Sep 21, 2016·Molecular Therapy. Nucleic Acids·Elena MorozJean-Christophe Leroux
Oct 13, 2016·Scientific Reports·Lodewijk J A ToonenWilleke M C van Roon-Mom
Oct 19, 2016·Nucleic Acid Therapeutics·João Casaca-CarreiraAli Jahanshahi
Jan 9, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Kevin Ita
Mar 1, 2017·Nature Biotechnology·Olga Khorkova, Claes Wahlestedt
Mar 1, 2017·Nature Biotechnology·Stanley T CrookeXue-Hai Liang
Apr 6, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Valentina SardoneMaria Sofia Falzarano
Nov 1, 2017·Organic & Biomolecular Chemistry·Fengmin GuoChuanzheng Zhou
Dec 2, 2017·Nature Reviews. Neurology·Carlo Rinaldi, Matthew J A Wood
Nov 7, 2017·Muscle & Nerve·Neelam Goyal, Pushpa Narayanaswami
Nov 30, 2018·Brain : a Journal of Neurology·Emma L ClaytonAdrian M Isaacs
Feb 8, 2018·Molecular and Cellular Pediatrics·Kelly M MartinovichStephen M Stick
Feb 16, 2019·Acta Neuropathologica Communications·Santosh JadhavNorbert Zilka
Feb 2, 2018·The Open Medicinal Chemistry Journal·Michael G KallitsakisKonstantinos E Litinas
Jun 12, 2019·Expert Review of Neurotherapeutics·Hassaan Bashir
Jun 28, 2019·The Journal of Gene Medicine·Fazhan WangXiangrong Song
Aug 14, 2019·Wiley Interdisciplinary Reviews. RNA·Carla NecklesNatasha J Caplen
Jun 24, 2017·Journal of Neurochemistry·Mark HallidayGiovanna R Mallucci
Dec 23, 2017·Frontiers in Molecular Neuroscience·Andrew P Tosolini, James N Sleigh
Nov 20, 2019·Expert Opinion on Drug Discovery·Kenneth K W ToWilliam C S Cho
Oct 25, 2017·Beilstein Journal of Organic Chemistry·Neha RanaAshok K Prasad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotide Therapies: ND

Antisense oligonucleotides are synthetic DNA oligomers that hybridize to a target RNA. This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.